NICE Endorses Obecabtagene Autoleucel Therapy f...

By João L. Carapinha

November 25, 2025

NICE Backs Obecabtagene Autoleucel The National Institute for Health and Care Excellence (NICE) recommended obecabtagene autoleucel therapy, a UK-dev...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...
Addressing AI Polyp Detection Gaps: A Roadmap for Evidence Generation and NHS...
Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Emblaveo MDR Infections: Evaluating a New Solution for Multidrug-Resistant Gr...
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges
CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Red...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Accelerated UK Clinical Trial Reforms: Enhancing Approvals with AI and Effici...
Antidepressant Side Effects: New Insights on Cardiometabolic Health Risks
AI Chatbot Delusions: Navigating the Risks of Validation in Mental Health
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...